Unlike recent deals for psoriasis drugs, Prurisol may qualify for three or five years of market exclusivity if approved. If its annual sales is 50% of Otezla ($500M), that's an additional $1.5B (3 years) or $2.5B (5 years) of revenue. I'm sure Leo will point that out to the potential partner, in addition to the smaller cost for Phase 3.

Quote:

---

I'm sure the partner they are going announce will want to get it through quickly also and cost will be less of an issue to them!

---